carvedilol has been researched along with Sensitivity and Specificity in 26 studies
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fourteen digitalised patients diagnosed with heart failure (NYHA Functional class II) with idiopathic dilated cardiomyopathy in chronic established atrial fibrillation were administered carvedilol in addition to their anti-heart failure medications in an attempt to improve their heart rate control." | 9.09 | Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. ( Agarwal, AK; Venugopalan, P, 2001) |
| "Forty-four patients with chronic congestive heart failure were enrolled in the study to randomly receive carvedilol or bisoprolol in addition to background therapy." | 5.12 | Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker? ( Hua, C; Hua, L; Huang, J; Huang, Y; Jiang, W; Li, F; Li, N; Li, Y; Wang, F; Wu, Y; Xu, Z, 2007) |
| "Fourteen digitalised patients diagnosed with heart failure (NYHA Functional class II) with idiopathic dilated cardiomyopathy in chronic established atrial fibrillation were administered carvedilol in addition to their anti-heart failure medications in an attempt to improve their heart rate control." | 5.09 | Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. ( Agarwal, AK; Venugopalan, P, 2001) |
| " Two strategies were evaluated: (1) conventional therapy (conventional)-the risks for death and hospitalization were derived from the angiotensin-converting enzyme inhibitor arm of the SOLVD treatment trial; and (2) pacemaker insertion with atrial pacing and carvedilol therapy (pacemaker-carvedilol)-risk reductions for death and CHF-related hospitalizations for carvedilol compared with conventional therapy were derived from the US Carvedilol Heart Failure Study." | 3.73 | Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia. ( Aaronson, KD; Fendrick, AM; Knight, BP; Stecker, EC, 2006) |
| " The validated assay was successfully applied to the quantification of the (R)- and (S)-enantiomers of both carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma in support of a human pharmacokinetic study." | 2.77 | A validated enantioselective LC-MS/MS assay for the simultaneous determination of carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma: application to a clinical pharmacokinetic study. ( Furlong, MT; He, B; Mariannino, T; Mylott, W; Shen, J; Stouffer, B; Zhao, S, 2012) |
| "Bioequivalence data for two pharmaceutical formulations (solid oral dosage forms) containing carvedilol is presented for both racemic and enantiomers of the active substance." | 2.73 | Achiral-chiral LC/LC-FLD coupling for determination of carvedilol in plasma samples for bioequivalence purposes. ( Albu, F; David, V; Galaon, T; Georgita, C; Medvedovici, A; Sora, DI; Udrescu, S, 2007) |
| " The dosage of beta-blockers were increased gradually to target or the tolerant dosages (bisoprolol 10 mg qd, carvedilol 25 mg bid) during 3 months in 36 patients." | 2.71 | [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure]. ( Bian, WY; Duan, B; Jia, X; Li, W; Li, YS; Wang, F; Wang, L; Xu, ZM, 2005) |
| "Carvedilol is an antihypertensive drug, which is available in clinical practice as a racemic mixture." | 1.43 | Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study. ( Coelho, EB; Lanchote, VL; Marques, MP; Nardotto, GHB, 2016) |
| "Severe aortic regurgitation was induced by retrograde puncture of the aortic valve leaflets under sonographic guidance in 12-week-old male C57BL/6J mice." | 1.42 | Characterization of coronary flow reserve and left ventricular remodeling in a mouse model of chronic aortic regurgitation with carvedilol intervention. ( Ge, J; Qian, J; Wang, X; Wu, J; You, J; Zhu, D; Zou, Y, 2015) |
| "Carvedilol enantiomers were extracted from human serum (0." | 1.40 | Enantioselective and sensitive determination of carvedilol in human plasma using chiral stationary-phase column and reverse-phase liquid chromatography with tandem mass spectrometry. ( Huang, Y; Jiang, J; Li, Y; Tian, L; Yan, Y, 2014) |
| "Carvedilol (CV) is an antagonist of alpha1 and beta1,beta2 membrane adrenoceptors and also a modulator of cardiac electrophysiological properties." | 1.35 | HPLC analysis, isolation and identification of a new degradation product in carvedilol tablets. ( Antoniadou-Vyza, E; Galanopoulou, O; Rozou, S, 2008) |
| "Letrozole was used as internal standard." | 1.34 | Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies. ( Foroutan, SM; Khoddam, A; Shafaati, A; Zarghi, A, 2007) |
| "Carvedilol is a beta/alpha1-adrenoceptor blocker." | 1.32 | Measurement of carvedilol in plasma by high-performance liquid chromatography with electrochemical detection. ( Kakinoki, S; Machida, M; Nomura, A; Takechi, S; Watanabe, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (76.92) | 29.6817 |
| 2010's | 6 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H | 1 |
| Sun, J | 1 |
| Sui, X | 1 |
| Liu, J | 1 |
| Yan, Z | 1 |
| Liu, X | 1 |
| Sun, Y | 1 |
| He, Z | 1 |
| Patel, DP | 1 |
| Sharma, P | 1 |
| Sanyal, M | 1 |
| Singhal, P | 1 |
| Shrivastav, PS | 1 |
| Jiang, J | 1 |
| Tian, L | 1 |
| Huang, Y | 2 |
| Yan, Y | 1 |
| Li, Y | 2 |
| Wang, X | 1 |
| Wu, J | 1 |
| Zhu, D | 1 |
| You, J | 1 |
| Zou, Y | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Nardotto, GHB | 1 |
| Coelho, EB | 1 |
| Marques, MP | 1 |
| Lanchote, VL | 1 |
| Galanopoulou, O | 1 |
| Rozou, S | 1 |
| Antoniadou-Vyza, E | 1 |
| Silva, RA | 1 |
| Wang, CC | 1 |
| Fernández, LP | 1 |
| Masi, AN | 1 |
| Auerbach, SR | 1 |
| Richmond, ME | 1 |
| Lamour, JM | 1 |
| Blume, ED | 1 |
| Addonizio, LJ | 1 |
| Shaddy, RE | 1 |
| Mahony, L | 1 |
| Pahl, E | 1 |
| Hsu, DT | 1 |
| Furlong, MT | 1 |
| He, B | 1 |
| Mylott, W | 1 |
| Zhao, S | 1 |
| Mariannino, T | 1 |
| Shen, J | 1 |
| Stouffer, B | 1 |
| Ptácek, P | 1 |
| Macek, J | 1 |
| Klíma, J | 1 |
| Machida, M | 1 |
| Watanabe, M | 1 |
| Takechi, S | 1 |
| Kakinoki, S | 1 |
| Nomura, A | 1 |
| Fukuchi, K | 1 |
| Yasumura, Y | 1 |
| Kiso, K | 1 |
| Hayashida, K | 1 |
| Miyatake, K | 1 |
| Ishida, Y | 1 |
| Kasama, S | 1 |
| Toyama, T | 1 |
| Kumakura, H | 1 |
| Takayama, Y | 1 |
| Ichikawa, S | 1 |
| Tange, S | 1 |
| Suzuki, T | 1 |
| Kurabayashi, M | 1 |
| Finsterer, S | 1 |
| Nentwich, Ch | 1 |
| Silber, S | 1 |
| do Carmo Borges, NC | 1 |
| Mendes, GD | 1 |
| de Oliveira Silva, D | 1 |
| Marcondes Rezende, V | 1 |
| Barrientos-Astigarraga, RE | 1 |
| De Nucci, G | 1 |
| Wang, F | 2 |
| Xu, ZM | 1 |
| Wang, L | 1 |
| Bian, WY | 1 |
| Jia, X | 1 |
| Duan, B | 1 |
| Li, W | 1 |
| Li, YS | 1 |
| Stecker, EC | 1 |
| Fendrick, AM | 1 |
| Knight, BP | 1 |
| Aaronson, KD | 1 |
| Saito, M | 1 |
| Kawana, J | 1 |
| Ohno, T | 1 |
| Kaneko, M | 1 |
| Mihara, K | 1 |
| Hanada, K | 1 |
| Sugita, R | 1 |
| Okada, N | 1 |
| Oosato, S | 1 |
| Nagayama, M | 1 |
| Sumiyoshi, T | 1 |
| Ogata, H | 1 |
| Medvedovici, A | 1 |
| Albu, F | 1 |
| Georgita, C | 1 |
| Sora, DI | 1 |
| Galaon, T | 1 |
| Udrescu, S | 1 |
| David, V | 1 |
| Zarghi, A | 1 |
| Foroutan, SM | 1 |
| Shafaati, A | 1 |
| Khoddam, A | 1 |
| Lim, HK | 1 |
| Chen, J | 1 |
| Sensenhauser, C | 1 |
| Cook, K | 1 |
| Subrahmanyam, V | 1 |
| Li, N | 1 |
| Jiang, W | 1 |
| Huang, J | 1 |
| Xu, Z | 1 |
| Hua, L | 1 |
| Hua, C | 1 |
| Wu, Y | 1 |
| Li, F | 1 |
| Deñola, NL | 1 |
| Quiming, NS | 1 |
| Saito, Y | 1 |
| Jinno, K | 1 |
| Gregory, D | 1 |
| Udelson, JE | 1 |
| Konstam, MA | 1 |
| Agarwal, AK | 1 |
| Venugopalan, P | 1 |
| Kondo, I | 1 |
| Mizushige, K | 1 |
| Nozaki, S | 1 |
| Iwado, Y | 1 |
| Hirao, K | 1 |
| Senda, S | 1 |
| Kohno, M | 1 |
| Matsuo, H | 1 |
2 reviews available for carvedilol and Sensitivity and Specificity
| Article | Year |
|---|---|
[The value of BNP determination in general practice].
Topics: Acute Disease; Antihypertensive Agents; Biomarkers; Carbazoles; Carvedilol; Clinical Trials as Topic | 2004 |
Economic impact of beta blockade in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Cost-Bene | 2001 |
9 trials available for carvedilol and Sensitivity and Specificity
| Article | Year |
|---|---|
UPLC-MS/MS assay for the simultaneous quantification of carvedilol and its active metabolite 4'-hydroxyphenyl carvedilol in human plasma to support a bioequivalence study in healthy volunteers.
Topics: Adult; Carbazoles; Carvedilol; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Stabil | 2013 |
A validated enantioselective LC-MS/MS assay for the simultaneous determination of carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma: application to a clinical pharmacokinetic study.
Topics: Administration, Oral; Adrenergic Antagonists; Biotransformation; Calibration; Carbazoles; Carvedilol | 2012 |
Gated myocardial SPECT to predict response to beta-blocker therapy in patients with idiopathic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Bisoprolol; Carbazoles; Cardiomyopathy, Dilat | 2004 |
Dobutamine stress 99mTc-tetrofosmin quantitative gated SPECT predicts improvement of cardiac function after carvedilol treatment in patients with dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dobutamin | 2004 |
Quantification of carvedilol in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry: application to bioequivalence study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chromatography, High Pressure Liquid; Humans; P | 2005 |
[Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Car | 2005 |
Achiral-chiral LC/LC-FLD coupling for determination of carvedilol in plasma samples for bioequivalence purposes.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Calibration; Carbazoles; Carvedilol; Chromatography, | 2007 |
Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker?
Topics: Adrenergic beta-Antagonists; Biomarkers; Bisoprolol; Carbazoles; Carvedilol; Female; Heart Failure; | 2007 |
Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Atrial Fibrillation; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Digitalis Glycosi | 2001 |
15 other studies available for carvedilol and Sensitivity and Specificity
| Article | Year |
|---|---|
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metab | 2009 |
Enantioselective and sensitive determination of carvedilol in human plasma using chiral stationary-phase column and reverse-phase liquid chromatography with tandem mass spectrometry.
Topics: Carbazoles; Carvedilol; Chromatography, Reverse-Phase; Drug Stability; Humans; Least-Squares Analysi | 2014 |
Characterization of coronary flow reserve and left ventricular remodeling in a mouse model of chronic aortic regurgitation with carvedilol intervention.
Topics: Animals; Aortic Valve Insufficiency; Carbazoles; Carvedilol; Chronic Disease; Echocardiography; Frac | 2015 |
Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chromatography, Liquid; Diabetes Mellitus, Type | 2016 |
HPLC analysis, isolation and identification of a new degradation product in carvedilol tablets.
Topics: Acetonitriles; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Buffers; Calibration; Carb | 2008 |
Flow injection spectrofluorimetric determination of carvedilol mediated by micelles.
Topics: Analytic Sample Preparation Methods; Carbazoles; Carvedilol; Electrolytes; Flow Injection Analysis; | 2008 |
BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial.
Topics: Adrenergic beta-Antagonists; Age Factors; Biomarkers; Carbazoles; Cardiomyopathies; Carvedilol; Chi- | 2010 |
Liquid chromatographic determination of carvedilol in human plasma.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Chromatography, High Pressure Liquid; Humans; Propa | 2003 |
Measurement of carvedilol in plasma by high-performance liquid chromatography with electrochemical detection.
Topics: Antihypertensive Agents; Calibration; Carbazoles; Carvedilol; Chromatography, High Pressure Liquid; | 2003 |
Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia.
Topics: Adrenergic beta-Antagonists; Bradycardia; Carbazoles; Carvedilol; Comorbidity; Cost-Benefit Analysis | 2006 |
Enantioselective and highly sensitive determination of carvedilol in human plasma and whole blood after administration of the racemate using normal-phase high-performance liquid chromatography.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calibration; Carbazoles; Carvedilol; Chro | 2006 |
Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies.
Topics: Acetonitriles; Administration, Oral; Adrenergic beta-Antagonists; Area Under Curve; Buffers; Calibra | 2007 |
Metabolite identification by data-dependent accurate mass spectrometric analysis at resolving power of 60,000 in external calibration mode using an LTQ/Orbitrap.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chromatography, High Pressure Liquid; Humans; M | 2007 |
Simultaneous enantioseparation and sensitivity enhancement of basic drugs using large-volume sample stacking.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; beta-Cyclodextrins; Calibration; Carbazoles; Ca | 2007 |
Ultrasonic tissue characterization can predict beta-blocker efficacy in dilated cardiomyopathy.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; | 2001 |